Sensorion SA (EPA:ALSEN)

France flag France · Delayed Price · Currency is EUR
0.3680
-0.0300 (-7.54%)
Oct 7, 2025, 4:30 PM CET
-7.54%
Market Cap111.78M
Revenue (ttm)5.65M
Net Income (ttm)-28.09M
Shares Out300.49M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume918,998
Average Volume492,996
Open0.4070
Previous Close0.3980
Day's Range0.3680 - 0.4150
52-Week Range0.1544 - 0.8140
Beta0.82
RSI83.11
Earnings DateSep 18, 2025

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 63
Stock Exchange Euronext Paris
Ticker Symbol ALSEN
Full Company Profile

Financial Performance

In 2024, Sensorion's revenue was 6.65 million, an increase of 16.76% compared to the previous year's 5.70 million. Losses were -25.97 million, 17.7% more than in 2023.

Financial Statements

News

Sensorion reports 1H results

20 days ago - Seeking Alpha

Sensorion reports FY results

7 months ago - Seeking Alpha